四川和谐双马股份有限公司 董事会提名和薪酬委员会实施细则 | 第一章 | 总则 | | --- | --- | | 2 | | | 第二章 | 人员组成 | | 2 | | | 第三章 | 职责权限 | | 3 | | | 第四章 | 决策程序 | | 5 | | | 第五章 | 会议的召开与通知 | | 7 | | | 第六章 | 议事与表决程序 | | 7 | | | 第七章 | 回避制 | | | 度 9 | | 第八章 | 附 | 第一章 总则 第一条 为进一步规范四川和谐双马股份有限公司（以下简称"公 司"）董事及高级管理人员的选聘程序，建立健全考核和薪酬管理机 制，完善公司治理结构，根据《中华人民共和国公司法》（以下简称 "《公司法"》）《上市公司治理准则》《四川和谐双马股份有限公司章 程》（以下简称"《公司章程》"）及其他有关规定，公司设立董事会提 名和薪酬委员会（以下简称"提名和薪酬委员会"），并制定本实施细 则。 3 第二条 提名和薪酬委员会是董事会按照股东会决议设立的专门 工作机构，主要负责拟定董事、高级管理人员的选择标准和程序；对 董事、高级管理人员人选及其任职资格进行遴选、审核；制定董 ...

四川和谐双马股份有限公司 第二章 人员组成 第三条 审计委员会根据《公司章程》和本实施细则规定的职责 范围履行职责，独立工作，不受公司其他部门干涉。 2 第一章 总则 第一条 为强化四川和谐双马股份有限公司（以下简称"公司"） 董事会决策功能，实现对公司财务收支和各项经营活动的有效监督， 完善公司治理结构，提升公司治理水平，根据《中华人民共和国公司 法》（以下简称"《公司法》"）《中华人民共和国证券法》《上市公司治 理准则》《四川和谐双马股份有限公司章程》（以下简称"《公司章程》"） 及其他有关规定，公司设立董事会审计委员会（以下简称"审计委员 会"），并制定本实施细则。 第四条 审计委员会由三至五名董事组成，其中独立董事应占多 数并担任召集人。审计委员会成员应当为不在公司担任高级管理人员 的董事，其中，至少应有一名独立董事是会计专业人士并由该人士担 任召集人。 董事会审计委员会实施细则 | 第一章 | 总则 | | --- | --- | | 2 | | | 第二章 | 人员组成 | | 2 | | | 第三章 | 职责权限 | | 3 | | | 第四章 | 决策程序 | | 5 | | | 第五章 | ...

四川和谐双马股份有限公司 投资者关系管理制度 为了加强四川和谐双马股份有限公司（以下简称"公司"）与投资者和潜在 投资者（以下合称"投资者"）之间的信息沟通，切实建立公司与投资者的良好 沟通平台，完善公司治理结构，保护投资者特别是中小投资者的合法权益，形成 公司与投资者之间长期、稳定、和谐的良性互动关系，制定本制度。 第一章 总则 第一条 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市 公司投资者关系管理工作指引》《深圳证券交易所股票上市规则》《深圳证券交 易所上市公司自律监管指引第 1 号——主板上市公司规范运作》及其他有关法律 法规、《四川和谐双马股份有限公司章程》（以下简称"《公司章程》"）的规定， 制定本制度。 第二条 投资者关系管理是指公司通过便利股东权利行使、信息披露、互 动交流和诉求处理等工作，加强与投资者之间的沟通，增进投资者对公司的了 解和认同，以提升公司治理水平和企业整体价值，实现尊重投资者、回报投资 者、保护投资者目的的相关活动。 第三条 公司及其控股股东、实际控制人、董事、高级管理人员和工作人 员开展投资者关系管理工作，应当遵守法律法规和深圳证券交易所（以下简称 "深交所" ...

第二章 管理原则 第四条 公司从事委托理财应坚持"规范运作、防范风险、谨慎投资、保值增值"的原则，以 不影响公司正常经营和主营业务的发展为先决条件。 四川和谐双马股份有限公司 委托理财管理制度 第一章 总 则 第一条 为规范四川和谐双马股份有限公司（以下简称"公司"）及纳入公司合并财务报表范 围内的子公司以及非公司制的企业（以下简称"子公司"）委托理财业务的管理，有效控制风 险，提高投资收益，维护公司及股东利益，依据《中华人民共和国证券法》《深圳证券交易所 股票上市规则》和《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》 等法律、行政法规、规范性文件及《四川和谐双马股份有限公司章程》（以下简称"《公司章 程》"）的有关规定，结合公司的实际情况，特制定本制度。 第二条 本制度所称"委托理财"是指公司委托银行、信托、证券、基金、期货、保险资产管 理机构、金融资产投资公司等专业理财机构（以下简称"理财机构"）按照事先约定的投资策 略、风险承担和收益分配方式，对其财产进行投资和管理或者购买相关理财产品的行为。公司 委托理财所涉及的交易标的必须是低风险、流动性好、安全性高的理财产品。 第三条 本 ...

四川和谐双马股份有限公司 董事会战略委员会实施细则 第一章 总 则 第一条 为适应四川和谐双马股份有限公司（以下简称"公司"） 战略发展需要，增强公司核心竞争力，明确公司发展规划，健全投资 决策程序，加强决策科学性，提高重大投资决策的效益和决策的质量， 完善公司治理结构，根据《中华人民共和国公司法》（以下简称"《公 司法》"）《上市公司治理准则》《四川和谐双马股份有限公司章程》（以 下简称"《公司章程》"）及其他有关规定，公司设立董事会战略委员 会（以下简称"战略委员会"），并制定本实施细则。 第二条 战略委员会是董事会按照股东会决议设立的专门工作机 构，主要负责对公司长期发展战略和重大投资决策进行研究并提出建 议。 第二章 人员组成 第三条 战略委员会成员由三至五名董事组成，其中独立董事应 2 占多数。 第四条 战略委员会委员由董事长、二分之一以上独立董事或者 全体董事的三分之一以上提名，并由董事会选举产生。 第五条 战略委员会设主任（即，召集人）一名，由公司董事长 担任，负责召集和主持委员会会议。当战略委员会主任无法履行职责 时，由其指定一名其他委员代行其职权；战略委员会主任既不履行职 责，也不指定其他委 ...

四川和谐双马股份有限公司 内幕信息知情人登记管理制度 第一章 总则 第一条 为规范四川和谐双马股份有限公司（以下简称"公司"或"上市公 司"）的内幕信息管理，做好内幕信息保密工作，有效防范内幕交易等违规违法行 为，维护信息披露公平原则，保护投资者的合法权益，根据《中华人民共和国公司 法》《中华人民共和国证券法》《上市公司信息披露管理办法》《深圳证券交易所 股票上市规则》《上市公司监管指引第5号——上市公司内幕信息知情人登记管理 制度》等有关法律、法规和《四川和谐双马股份有限公司章程》（以下简称"《公 司章程》"）的有关规定，制定本制度。 第二条 本制度的适用范围：公司及公司下属各部门、分公司、合并报表范围 内的企业及公司能够对其实施重大影响的参投企业。 第三条 董事会秘书办公室是公司信息披露管理、投资者关系管理、内幕信息 登记备案的日常办事机构，并负责公司内幕信息的监管工作。 第四条 董事会秘书办公室负责证券监管机构、证券交易所、证券公司等机构 及新闻媒体、股东的接待、咨询（质询）、服务工作。 "尚未公开的信息"是指公司尚未在指定信息披露媒体正式公开的信息。 第十条 本制度所指内幕信息的范围包括但不限于以下重 ...

Group 1 - The core viewpoint of the article is that Sichuan Shuangma (SZ 000935) held its 16th meeting of the 9th Board of Directors on August 28, 2025, to discuss the proposal regarding the payment of mining rights transfer income [1] - For the year 2024, Sichuan Shuangma's revenue composition is as follows: cement manufacturing accounts for 55.28%, private equity investment management accounts for 42.07%, and biopharmaceutical business accounts for 2.65% [1] - As of the time of reporting, Sichuan Shuangma has a market capitalization of 15.4 billion yuan [1]

Important Notice, Table of Contents, and Definitions [Important Notice](index=2&type=section&id=Important%20Notice) The board and senior management guarantee report accuracy, advise on investment risks, and confirm no cash dividends or bonus shares for the period - The company's board of directors and senior management commit to the truthfulness, accuracy, and completeness of the report content, advising investors to pay attention to the risks and countermeasures in Section III 'Management Discussion and Analysis'[4](index=4&type=chunk) - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital during the reporting period[5](index=5&type=chunk) [Table of Contents](index=3&type=section&id=Table%20of%20Contents) This section lists the detailed table of contents, including company profile, management discussion and analysis, corporate governance, significant matters, share changes, bond information, financial reports, and other submitted data - The report's main sections include company profile and key financial indicators, management discussion and analysis, corporate governance, environment and society, significant matters, share changes and shareholder information, bond-related information, financial report, and a catalog of reference documents[7](index=7&type=chunk)[8](index=8&type=chunk) [Definitions](index=5&type=section&id=Definitions) This section provides definitions for common terms used in the report, covering company and subsidiary names, financial and investment terms, and biological and pharmaceutical professional terms to ensure clear understanding - The report defines abbreviations for the company and its subsidiaries, such as "Sichuan Shuangma", "Shuangma Yibin", and "Shenzhen Jianyuan"[10](index=10&type=chunk) - It explains professional terms in finance and investment, such as IPO (Initial Public Offering), VC (Venture Capital), and PE (Private Equity)[10](index=10&type=chunk) - Key concepts in the biopharmaceutical field are detailed, including ADC (Antibody-Drug Conjugate), peptides, GLP-1 (Glucagon-Like Peptide-1), CDMO (Contract Development and Manufacturing Organization), DMF filing (Drug Master File), and GMP/cGMP (Good Manufacturing Practice/current Good Manufacturing Practice)[10](index=10&type=chunk)[12](index=12&type=chunk) Company Profile and Key Financial Indicators [Company Profile](index=8&type=section&id=Company%20Profile) Sichuan Harmony Shuangma Co, Ltd, stock ticker "Sichuan Shuangma" and stock code 000935, is listed on the Shenzhen Stock Exchange, with Xie Jianping as its legal representative - The company's stock abbreviation is "Sichuan Shuangma", stock code 000935, listed on the Shenzhen Stock Exchange[15](index=15&type=chunk) - The company's legal representative is Xie Jianping[15](index=15&type=chunk) [Contact Person and Information](index=8&type=section&id=Contact%20Person%20and%20Information) The company's Board Secretary is Huang Canwen, Securities Affairs Representative is Jing Jing, with contact address in Chengdu, Sichuan, and provided phone, fax, and email - The Board Secretary is Huang Canwen, and the Securities Affairs Representative is Jing Jing[16](index=16&type=chunk) - The company's contact address is 26th Floor, Office Building 1, Chengdu International Finance Square, No 1, Section 3, Hongxing Road, Jinjiang District, Chengdu, Sichuan Province[16](index=16&type=chunk) - The investor inquiry hotline is 028-63231548, and the email address is public.sm@sc-shuangma.com[16](index=16&type=chunk) [Other Information](index=8&type=section&id=Other%20Information) During the reporting period, there were no changes to the company's registered address, office address, website, email, or information disclosure and archiving locations, with specific details available in the 2024 annual report - The company's contact information, information disclosure, and archiving locations remained unchanged during the reporting period, with specific details available in the 2024 annual report[17](index=17&type=chunk)[18](index=18&type=chunk) [Key Accounting Data and Financial Indicators](index=9&type=section&id=Key%20Accounting%20Data%20and%20Financial%20Indicators) During this reporting period, the company's operating revenue increased by 30.42% year-on-year, net profit attributable to shareholders increased by 13.42%, and net profit excluding non-recurring gains and losses increased by 70.14%, with total assets and net assets attributable to shareholders also growing Key Accounting Data and Financial Indicators (Current Reporting Period vs. Same Period Last Year) | Indicator | Current Reporting Period (RMB) | Same Period Last Year (RMB) | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 629,197,790.08 | 482,425,424.71 | 30.42% | | Net Profit Attributable to Shareholders of Listed Company | 128,592,907.80 | 113,380,825.19 | 13.42% | | Net Profit Attributable to Shareholders of Listed Company Excluding Non-recurring Gains and Losses | 161,776,715.50 | 95,083,548.35 | 70.14% | | Net Cash Flow from Operating Activities | 156,155,024.91 | 163,422,457.83 | -4.45% | | Basic Earnings Per Share (RMB/share) | 0.17 | 0.15 | 13.33% | | Diluted Earnings Per Share (RMB/share) | 0.17 | 0.15 | 13.33% | | Weighted Average Return on Net Assets | 1.71% | 1.53% | Increased by 0.18 percentage points | | **Period-End Indicators** | **Current Period-End (RMB)** | **Previous Year-End (RMB)** | **Change from Previous Year-End** | | Total Assets | 9,092,603,391.24 | 8,991,376,516.63 | 1.13% | | Net Assets Attributable to Shareholders of Listed Company | 7,603,913,228.64 | 7,475,317,745.70 | 1.72% | [Differences in Accounting Data under Domestic and Overseas Accounting Standards](index=9&type=section&id=Differences%20in%20Accounting%20Data%20under%20Domestic%20and%20Overseas%20Accounting%20Standards) During the reporting period, the company had no differences in net profit and net assets between financial reports disclosed under International Accounting Standards or overseas accounting standards and Chinese Accounting Standards - The company had no differences in net profit and net assets under domestic and overseas accounting standards during the reporting period[21](index=21&type=chunk)[22](index=22&type=chunk) [Non-Recurring Gains and Losses and Amounts](index=9&type=section&id=Non-Recurring%20Gains%20and%20Losses%20and%20Amounts) The total non-recurring gains and losses for this reporting period amounted to RMB -33,183,807.70, primarily due to the one-time impact of estimated limestone mining rights fees, combined with government subsidies and structured deposit income Non-Recurring Gains and Losses and Amounts | Item | Amount (RMB) | Explanation | | :--- | :--- | :--- | | Gains and losses from disposal of non-current assets | 6,388.04 | | | Government subsidies included in current profit and loss | 6,650,576.04 | Mainly due to subsidiaries receiving VAT refunds for comprehensive resource utilization and government support funds | | Gains and losses from entrusted investments or asset management | 206,035.80 | Structured deposit income | | One-time impact on current profit and loss due to adjustments in tax, accounting, and other laws and regulations | -45,895,612.00 | Estimated limestone mining rights fees for the period from July 1, 2017, to December 31, 2024, already consumed | | Other non-operating income and expenses apart from the above | 72,000.40 | | | Less: Income tax impact | -5,933,928.57 | | | Impact on minority interests (after tax) | 157,124.55 | | | Total | -33,183,807.70 | | Management Discussion and Analysis [Company's Main Businesses During the Reporting Period](index=11&type=section&id=Company%27s%20Main%20Businesses%20During%20the%20Reporting%20Period) The company primarily engages in industrial investment and management and private equity fund management, with core assets including building materials manufacturing, biopharmaceutical R&D and production, and private equity fund management companies; during the reporting period, the company's building materials business faced market challenges, biopharmaceutical business benefited from GLP-1 drug market expansion, and private equity investment business developed steadily under policy support - The company's main businesses cover building materials manufacturing, biopharmaceutical R&D and production, and private equity fund management[27](index=27&type=chunk) - The company's strategic positioning focuses on new industrialization, artificial intelligence, and biotechnology, aligning with national scientific and technological innovation to lead a modern industrial system, targeting new technologies, models, and consumption[31](index=31&type=chunk) [Company Introduction](index=11&type=section&id=Company%20Introduction) Sichuan Shuangma, established in 1998 and listed in 1999, primarily manages building materials, biopharmaceuticals, and private equity funds, with its building materials business in Yibin benefiting from regional infrastructure, its biopharmaceutical business centered on Shenzhen Jianyuan focusing on peptide R&D and production with global supply capabilities, and its private equity fund management business, Xizang Jinhe, managing nearly RMB 28 billion across diverse investment sectors - The company's building materials manufacturing business produces cement, commercial clinker, and aggregates, with annual capacities of 2 million tons and 5 million tons respectively, benefiting from infrastructure projects in Yibin City[28](index=28&type=chunk) - The company's biopharmaceutical business, centered on Shenzhen Jianyuan, specializes in peptide product R&D and production, covering peptide APIs, CDMO, and cosmetic peptides, with core APIs registered in multiple countries and global supply capabilities[29](index

Market Overview - On August 27, the diversified financial sector declined by 0.75% compared to the previous trading day, with Sichuan Shuangma leading the decline [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Stock Performance - Notable gainers included: - Zhongyou Capital (000617) with a closing price of 12.38, up 4.47% and a trading volume of 6.0894 million shares, totaling 7.561 billion yuan [1] - *ST Rendo (002647) closed at 5.82, up 1.39% with a trading volume of 248,400 shares, totaling 146 million yuan [1] - Major decliners included: - Sichuan Shuangma (000935) closed at 20.00, down 6.89% with a trading volume of 242,800 shares, totaling 501 million yuan [2] - Hongming (001236) closed at 12.53, down 4.79% with a trading volume of 311,400 shares, totaling 402 million yuan [2] Capital Flow - The diversified financial sector experienced a net outflow of 685 million yuan from institutional investors, while retail investors saw a net inflow of 762 million yuan [2] - The capital flow for key stocks showed: - Zhongyou Capital had a net inflow of 287.1 million yuan from institutional investors, while retail investors had a net outflow of 136 million yuan [3] - New Power Financial (600318) saw a net inflow of 77.59 million yuan from institutional investors, with retail investors experiencing a net outflow of 42.75 million yuan [3]

中国经济网北京8月27日讯 四川双马（000935）（000935.SZ）昨日晚间披露《关于持股5%以上股东减持股份的预 披露公告》。 根据公告，股东LAFARGE CHINA OFFSHORE HOLDING COMPANY（LCOHC）LTD.（以下简称"LCOHC"）计 划在公告披露之日起15个交易日后的连续90个自然日内以集中竞价和大宗交易方式合计减持公司股份不超过 7,572,200股（含本数），占公司总股本的0.9919%，占剔除公司回购专用证券账户中的股份数量后总股本的 1.0000%。其中，以集中竞价方式减持公司股份不超过3,786,100股（含本数），占剔除公司回购专用证券账户中的 股份数量后总股本的0.5000%，以大宗交易方式减持公司股份不超过3,786,100股（含本数），占剔除公司回购专用 证券账户中的股份数量后总股本的0.5000%。 股东天津赛克环企业管理中心（有限合伙）（以下简称"天津赛克环"）计划在公告披露之日起15个交易日后的连 续90个自然日内以集中竞价和大宗交易方式合计减持公司股份不超过7,572,200股（含本数），占公司总股本的 0.9919%，占剔除公司回购专用证 ...